Key result
GS-E3D dose-dependently reduced urinary levels of albumin, 8-OHdG, and AGEs, and inhibited mesangial expansion in streptozotocin-induced diabetic rats.
Why the study?
Does GS-E3D improve diabetes-related renal dysfunction in streptozotocin-induced diabetic rats?
Does GS-E3D improve diabetes-related renal dysfunction in streptozotocin-induced diabetic rats?
p-value: p=<0.05
In a rat model of streptozotocin-induced diabetes, oral administration of GS-E3D dose-dependently improved symptoms of diabetic nephropathy by inhibiting renal accumulation of AGEs and oxidative stress.
GS-E3D effects in diabetic rats merit clinical trials; leaves open translation to human diabetic nephropathy.
BACKGROUND: GS-E3D is a newly developed pectin lyase-modified red ginseng extract. The purpose of this study was to investigate the therapeutic effects of GS-E3D on diabetes-related renal dysfunction in streptozotocin-induced diabetic rats. METHOD: GS-E3D (25, 50, and 100 mg/kg body weight per day) was administered for 6 weeks. The levels of blood glucose and hemoglobin A1c, and of urinary albumin, 8-hydroxy-2'-deoxyguanosine (8-OHdG), and advanced glycation end-products (AGEs) were determined. Kidney histopathology, renal accumulation of AGEs, and expression of α-smooth muscle actin (α-SMA) were also examined. RESULTS: Administration of GS-E3D for 6 weeks reduced urinary levels of albumin, 8-OHdG, and AGEs in diabetic rats. Mesangial expansion, renal accumulation of AGEs, and enhanced α-SMA expression were significantly inhibited by GS-E3D treatment. Oral administration of GS-E3D dose-dependently improved all symptoms of diabetic nephropathy by inhibiting renal accumulation of AGEs and oxidative stress. CONCLUSION: The results of this study indicate that the use of GS-E3D as a food supplement may provide effective treatment of diabetes-induced renal dysfunction.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2017) studied Diabetic nephropathy (n=50). GS-E3D vs. Vehicle was evaluated on Urinary albumin, 8-OHdG, and AGEs levels (p=<0.05). GS-E3D dose-dependently reduced urinary levels of albumin, 8-OHdG, and AGEs, and inhibited mesangial expansion in streptozotocin-induced diabetic rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: